Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07060560

Presepsin Diagnostic Performance in Severe Burn Sepsis

Prospective Observational Study to Evaluate the Diagnostic Accuracy of Presepsin for Sepsis in Severe Burn Patients

Status
Recruiting
Phase
Study type
Observational
Enrollment
138 (estimated)
Sponsor
Dohern Kym · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study enrolls approximately 270 adult patients with severe burns covering at least 20% of total body surface area to evaluate how well the blood biomarker presepsin diagnoses sepsis early in this high-risk population. Sepsis-a life-threatening condition caused by an exaggerated immune response to infection-is particularly urgent to detect promptly in burn patients. Participants will undergo blood tests for presepsin at predefined time points, and these results will be compared to C-reactive protein (CRP), procalcitonin (PCT) levels, Sepsis-3 clinical criteria, and blood culture findings. The primary goal is to measure presepsin's sensitivity and specificity for sepsis detection, thereby determining its diagnostic accuracy. Findings from this study may enable faster sepsis treatment in severe burn patients and improve clinical outcomes.

Conditions

Timeline

Start date
2025-05-01
Primary completion
2026-05-01
Completion
2026-05-01
First posted
2025-07-11
Last updated
2025-08-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT07060560. Inclusion in this directory is not an endorsement.

Presepsin Diagnostic Performance in Severe Burn Sepsis (NCT07060560) · Clinical Trials Directory